Table 2 Medication use (any time on or after cohort entry)

N

132,672

106,098

21,871

6,653

csDMARD, n (%)

105,661 (79.6)

89,316 (84.2)

14,977 (68.5)

2,744 (41.2)

 Apremilast

3,518 (2.7)

470 (0.4)

3,150 (14.4)

73 (1.1)

 Chloroquine

67 (0.1)

61 (0.1)

5 (< 0.1)

1 (< 0.1)

 Hydroxychloroquine

44,350 (33.4)

42,346 (39.9)

1,759 (8.0)

676 (10.2)

 Leflunomide

20,692 (15.6)

18,425 (17.4)

2,161 (9.9)

348 (5.2)

 Methotrexate

61,346 (46.2)

51,456 (48.5)

9,393 (42.9)

1,260 (18.9)

 Sulfasalazine

16,346 (12.3)

13,049 (12.3)

2,415 (11.0)

1,084 (16.3)

bDMARD, n (%)

52,294 (39.4)

36,694 (34.6)

11,555 (52.8)

5,087 (76.5)

 Abatacept

2,671 (2.0)

5,233 (4.9)

460 (2.1)

34 (0.5)

 Adalimumab

22,283 (16.8)

14,154 (13.3)

5,963 (27.3)

2,691 (40.4)

 Anakinra

143 (0.1)

141 (0.1)

0 (0.0)

3 (< 0.1)

 Certolizumab pegol

6,352 (4.8)

4,199 (4.0)

1,567 (7.2)

751 (11.3)

 Etanercept

11,111 (8.4)

7,842 (7.4)

2,516 (11.5)

928 (13.9)

 Golimumab

6,425 (4.8)

4,351 (4.1)

1,469 (6.7)

779 (11.7)

 Infliximab

6,198 (4.7)

3,985 (3.8)

1,553 (7.1)

831 (12.5)

 Rituximab

2,835 (2.1)

2,762 (2.6)

70 (0.3)

19 (0.3)

 Sarilumab

615 (0.5)

605 (0.6)

9 (< 0.1)

5 (0.1)

 Tocilizumab

2,333 (1.8)

2,318 (2.2)

20 (0.1)

12 (0.2)

JAK inhibitors, n (%)

10,006 (7.5)

8,755 (8.3)

1,194 (5.5)

212 (3.2)

 Baricitinib

452 (0.3)

440 (0.4)

13 (0.1)

4 (0.1)

 Tofacitinib

7,170 (5.4)

6,150 (5.8)

1,006 (4.6)

116 (1.7)

 Upadacitinib

3,381 (2.5)

3,092 (2.9)

240 (1.1)

110 (1.7)

NSAIDs, n (%)

67,858 (51.1)

53,753 (50.7)

11,453 (52.4)

3,765 (56.6)

Glucocorticoids (prednisone equivalent)^a, n (%)

 None

32,775 (24.7)

20,003 (18.9)

10,174 (46.5)

3,279 (49.3)

  ≤ 7.5 mg/day

33,967 (25.6)

30,951 (29.2)

2,683 (12.3)

671 (10.1)

  > 7.5 mg/day

65,930 (49.7)

55,144 (52.0)

9,014 (41.2)

2,703 (40.6)